Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group.
about
Retinoic acid post consolidation therapy for high-risk neuroblastoma patients treated with autologous hematopoietic stem cell transplantationHigh-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastomaRapid COJEC versus standard induction therapies for high-risk neuroblastomaRapid COJEC versus standard induction therapies for high-risk neuroblastomaHigh-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastomaIodine-131-meta-iodobenzylguanidine therapy for patients with high-risk neuroblastomaRetinoic acid post consolidation therapy for high-risk neuroblastomaHigh-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastomaHigh-dose chemotherapy for children and young adults with stage IV rhabdomyosarcomaHigh dose chemotherapy for children and young adults with stage IV rhabdomyosarcomaTRIM16 acts as a tumour suppressor by inhibitory effects on cytoplasmic vimentin and nuclear E2F1 in neuroblastoma cellsZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcomeThe estrogen-responsive B box protein is a novel regulator of the retinoid signalAre experimental treatments for cancer in children superior to established treatments? Observational study of randomised controlled trials by the Children's Oncology GroupNeuroblastoma-derived secretory protein is a novel secreted factor overexpressed in neuroblastomaAnti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastomaStem cell transplantation for neuroblastomaNetrin-1 acts as a survival factor for aggressive neuroblastomaCommon variations in BARD1 influence susceptibility to high-risk neuroblastomaIdentification of ALK as a major familial neuroblastoma predisposition geneChromosome 6p22 locus associated with clinically aggressive neuroblastomaCorrelation of elevated level of blood midkine with poor prognostic factors of human neuroblastomasProgress in childhood cancer: 50 years of research collaboration, a report from the Children's Oncology GroupLong-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group studyCancer Stem Cells and Their Interaction with the Tumor Microenvironment in NeuroblastomaEnhancing Cancer Immunotherapy Via Activation of Innate ImmunityRole of Retinoic Acid-Metabolizing Cytochrome P450s, CYP26, in Inflammation and CancerNotch: a key regulator of tumor angiogenesis and metastasisNeuroblastoma: issues in transplantationNuclear GRP75 binds retinoic acid receptors to promote neuronal differentiation of neuroblastomaActivating mutations in ALK provide a therapeutic target in neuroblastoma.Low expression of Wnt-5a gene is associated with high-risk neuroblastomaTreatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapyBioavailability and dose-dependent anti-tumour effects of 9-cis retinoic acid on human neuroblastoma xenografts in ratInvolvement of reactive oxygen species in 2-methoxyestradiol-induced apoptosis in human neuroblastoma cellsNeuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virusOrganometallic iron(III)-salophene exerts cytotoxic properties in neuroblastoma cells via MAPK activation and ROS generationTargeting neuroblastoma stem cells with retinoic acid and proteasome inhibitorTumour heterogeneity and cancer cell plasticityOverview and recent advances in the treatment of neuroblastoma.
P2860
Q24186451-4DDDA660-6E3C-40FD-AC96-BEF3BF9BA4B4Q24186636-DD00A9D5-6943-4AD1-A050-B7C362AF2152Q24187922-7DE25CAB-844C-4859-9756-955BA0CB2DCFQ24197871-07B1CE7F-1A86-46B9-860E-D62BED8A428CQ24200296-3F0C65C7-88D4-4DF0-8BDC-6054C0B2989FQ24201280-E185BDED-3260-4FFA-AF07-C0ACC020CD0AQ24201495-1ACC888B-1ADB-4A17-B32F-50159F3F8733Q24235309-5A4A81C6-D7B3-478E-86D6-856C534E426EQ24235604-60C7100B-0F6C-430E-957B-4EDDD28F7255Q24244808-1AA52D5F-831F-4996-8B1E-4DF90ACA4FC1Q24297046-AF7BDF82-0E60-4C2A-8159-A21D8897D7D1Q24313063-5D7D7C83-D924-43CD-85EF-DE3F7F6A0C23Q24319942-A99F8270-F8CD-4502-90F1-DE7CCD120D6AQ24536914-0F3EE10C-DA84-43B1-B9F7-CAAFFF7D17F0Q24594695-3CA9C763-AD25-4983-9976-72C2B014B3C0Q24602657-640CC19C-C3B8-4D27-BDA0-21F2BBA25111Q24629221-61275FC6-4E72-48DF-A694-18AD577BEAA7Q24645254-8B9685BF-8AF6-49F7-8424-654F5A614C71Q24645352-15CC3BEA-7EC2-46ED-AB27-5E7E7A3B79C3Q24655923-6DFE25A4-B169-43F0-8693-54B9C6140985Q24656264-8ACDA1BF-A145-491F-8881-56C42938F711Q24656678-2AAA1F9B-7614-4EEA-8437-A79BB55C25B6Q24657000-A6332185-333D-4D64-8BB2-ED6943416256Q24658339-EAC7AC27-34E2-45DC-8BEF-30A7E80C492CQ26771238-5CFBC6C4-792F-45A7-A811-0BFADAC80F61Q26796313-657D3C62-1FA1-40AC-9728-1803C029B3C1Q26800202-3BC0B3E2-73DA-4D5F-BE40-3930266E4759Q26858778-8A43AB15-4BB0-42E3-96AF-35C44AD9FBE2Q27008197-DE0C17CD-A196-4C21-B792-A1D7078D8B6EQ27316571-00202453-71E8-4622-A40D-BCDCF64D7436Q27851452-7457B2B2-AC0B-4FD1-9A89-1A8F169B8C37Q28297914-C48178D4-DB1A-4E2C-B7F6-A5DFAF7A7C86Q28350866-989B4F0F-16F5-43F0-968C-D4FEC478FCCAQ28366600-31C291A1-2F88-4FE1-A9FB-E00E54DC0121Q28394171-BE4DF0D8-5CC6-4098-B273-21C253DE0D1AQ28474594-6B8665B9-F7E3-4A7E-B0E0-3FD08C298931Q28477973-EB8F28C8-B9F7-4467-9203-9127008FC210Q28534151-50564C3B-0472-4A15-9A15-1F5B69005C8FQ29617990-B8491A7E-A742-4A82-BA8D-CFA7ACB0D364Q30238693-D190CD86-5A45-42DF-B165-17F0176D054D
P2860
Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group.
description
1999 nî lūn-bûn
@nan
1999 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Treatment of high-risk neurobl ...... acid. Children's Cancer Group.
@ast
Treatment of high-risk neurobl ...... acid. Children's Cancer Group.
@en
type
label
Treatment of high-risk neurobl ...... acid. Children's Cancer Group.
@ast
Treatment of high-risk neurobl ...... acid. Children's Cancer Group.
@en
prefLabel
Treatment of high-risk neurobl ...... acid. Children's Cancer Group.
@ast
Treatment of high-risk neurobl ...... acid. Children's Cancer Group.
@en
P2093
P921
P1476
Treatment of high-risk neurobl ...... acid. Children's Cancer Group.
@en
P2093
Brodeur GM
Gerbing RB
Matthay KK
Reynolds CP
P304
P356
10.1056/NEJM199910143411601
P407
P577
1999-10-01T00:00:00Z